vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and OPEN TEXT CORP (OTEX). Click either name above to swap in a different company.
OPEN TEXT CORP is the larger business by last-quarter revenue ($1.3B vs $708.5M, roughly 1.9× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 12.7%, a 6.4% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -0.6%). OPEN TEXT CORP produced more free cash flow last quarter ($279.4M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -4.3%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Open Text Corporation is a global software company that develops and sells information management software.
MEDP vs OTEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.3B |
| Net Profit | $135.1M | $168.1M |
| Gross Margin | — | 74.0% |
| Operating Margin | 21.6% | 22.0% |
| Net Margin | 19.1% | 12.7% |
| Revenue YoY | 32.0% | -0.6% |
| Net Profit YoY | 15.5% | -26.9% |
| EPS (diluted) | $4.65 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.3B | ||
| Q3 25 | $659.9M | $1.3B | ||
| Q2 25 | $603.3M | $1.3B | ||
| Q1 25 | $558.6M | $1.3B | ||
| Q4 24 | $536.6M | $1.3B | ||
| Q3 24 | $533.3M | $1.3B | ||
| Q2 24 | $528.1M | $1.4B | ||
| Q1 24 | $511.0M | $1.4B |
| Q4 25 | $135.1M | $168.1M | ||
| Q3 25 | $111.1M | $146.6M | ||
| Q2 25 | $90.3M | $28.8M | ||
| Q1 25 | $114.6M | $92.8M | ||
| Q4 24 | $117.0M | $229.9M | ||
| Q3 24 | $96.4M | $84.4M | ||
| Q2 24 | $88.4M | $248.2M | ||
| Q1 24 | $102.6M | $98.3M |
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 72.8% | ||
| Q2 25 | — | 72.3% | ||
| Q1 25 | — | 71.6% | ||
| Q4 24 | — | 73.3% | ||
| Q3 24 | — | 71.7% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 73.0% |
| Q4 25 | 21.6% | 22.0% | ||
| Q3 25 | 21.5% | 21.0% | ||
| Q2 25 | 20.9% | 13.9% | ||
| Q1 25 | 20.3% | 16.7% | ||
| Q4 24 | 23.4% | 22.2% | ||
| Q3 24 | 21.1% | 16.3% | ||
| Q2 24 | 19.9% | 14.2% | ||
| Q1 24 | 20.4% | 15.7% |
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 16.8% | 11.4% | ||
| Q2 25 | 15.0% | 2.2% | ||
| Q1 25 | 20.5% | 7.4% | ||
| Q4 24 | 21.8% | 17.2% | ||
| Q3 24 | 18.1% | 6.6% | ||
| Q2 24 | 16.7% | 18.2% | ||
| Q1 24 | 20.1% | 6.8% |
| Q4 25 | $4.65 | $0.66 | ||
| Q3 25 | $3.86 | $0.58 | ||
| Q2 25 | $3.10 | $0.11 | ||
| Q1 25 | $3.67 | $0.35 | ||
| Q4 24 | $3.67 | $0.87 | ||
| Q3 24 | $3.01 | $0.32 | ||
| Q2 24 | $2.75 | $0.91 | ||
| Q1 24 | $3.20 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $1.3B |
| Total DebtLower is stronger | — | $6.4B |
| Stockholders' EquityBook value | $459.1M | $4.0B |
| Total Assets | $2.0B | $13.6B |
| Debt / EquityLower = less leverage | — | 1.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $1.3B | ||
| Q3 25 | $285.4M | $1.1B | ||
| Q2 25 | $46.3M | $1.2B | ||
| Q1 25 | $441.4M | $1.3B | ||
| Q4 24 | $669.4M | $1.1B | ||
| Q3 24 | $656.9M | $1.0B | ||
| Q2 24 | $510.9M | $1.3B | ||
| Q1 24 | $407.0M | $1.1B |
| Q4 25 | — | $6.4B | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.4B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.4B | ||
| Q1 24 | — | $8.4B |
| Q4 25 | $459.1M | $4.0B | ||
| Q3 25 | $293.6M | $4.0B | ||
| Q2 25 | $172.4M | $3.9B | ||
| Q1 25 | $593.6M | $4.1B | ||
| Q4 24 | $825.5M | $4.2B | ||
| Q3 24 | $881.4M | $4.1B | ||
| Q2 24 | $763.6M | $4.2B | ||
| Q1 24 | $671.5M | $4.1B |
| Q4 25 | $2.0B | $13.6B | ||
| Q3 25 | $1.8B | $13.5B | ||
| Q2 25 | $1.6B | $13.8B | ||
| Q1 25 | $1.9B | $13.8B | ||
| Q4 24 | $2.1B | $13.7B | ||
| Q3 24 | $2.1B | $13.8B | ||
| Q2 24 | $1.9B | $14.2B | ||
| Q1 24 | $1.8B | $16.4B |
| Q4 25 | — | 1.58× | ||
| Q3 25 | — | 1.61× | ||
| Q2 25 | — | 1.62× | ||
| Q1 25 | — | 1.55× | ||
| Q4 24 | — | 1.51× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 2.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $318.7M |
| Free Cash FlowOCF − Capex | $188.1M | $279.4M |
| FCF MarginFCF / Revenue | 26.6% | 21.1% |
| Capex IntensityCapex / Revenue | 0.6% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.90× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $878.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $318.7M | ||
| Q3 25 | $246.2M | $147.8M | ||
| Q2 25 | $148.5M | $158.2M | ||
| Q1 25 | $125.8M | $402.2M | ||
| Q4 24 | $190.7M | $348.0M | ||
| Q3 24 | $149.1M | $-77.8M | ||
| Q2 24 | $116.4M | $185.2M | ||
| Q1 24 | $152.7M | $384.7M |
| Q4 25 | $188.1M | $279.4M | ||
| Q3 25 | $235.5M | $101.2M | ||
| Q2 25 | $142.4M | $124.0M | ||
| Q1 25 | $115.8M | $373.8M | ||
| Q4 24 | $183.0M | $306.7M | ||
| Q3 24 | $138.5M | $-117.1M | ||
| Q2 24 | $103.5M | $145.2M | ||
| Q1 24 | $147.2M | $348.2M |
| Q4 25 | 26.6% | 21.1% | ||
| Q3 25 | 35.7% | 7.9% | ||
| Q2 25 | 23.6% | 9.5% | ||
| Q1 25 | 20.7% | 29.8% | ||
| Q4 24 | 34.1% | 23.0% | ||
| Q3 24 | 26.0% | -9.2% | ||
| Q2 24 | 19.6% | 10.7% | ||
| Q1 24 | 28.8% | 24.1% |
| Q4 25 | 0.6% | 3.0% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.8% | 2.3% | ||
| Q4 24 | 1.4% | 3.1% | ||
| Q3 24 | 2.0% | 3.1% | ||
| Q2 24 | 2.4% | 2.9% | ||
| Q1 24 | 1.1% | 2.5% |
| Q4 25 | 1.43× | 1.90× | ||
| Q3 25 | 2.22× | 1.01× | ||
| Q2 25 | 1.65× | 5.49× | ||
| Q1 25 | 1.10× | 4.33× | ||
| Q4 24 | 1.63× | 1.51× | ||
| Q3 24 | 1.55× | -0.92× | ||
| Q2 24 | 1.32× | 0.75× | ||
| Q1 24 | 1.49× | 3.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
OTEX
| Transferred At Point In Time | $184.2M | 14% |
| Cybersecurity Enterprise Product | $174.5M | 13% |
| Business Network Product | $159.8M | 12% |
| Business Network Cloud Services And Subscriptions | $151.4M | 11% |
| Content Cloud Services And Subscriptions | $137.9M | 10% |
| Cybersecurity SMB Consumer Product | $127.6M | 10% |
| Application Delivery Management Product | $120.1M | 9% |
| IT Operations Management Product | $113.3M | 9% |
| Professional Service And Other | $82.5M | 6% |
| Analytics Product | $58.1M | 4% |
| IT Operations Management Cloud Services And Subscriptions | $7.8M | 1% |
